Roche’s Genentech unit said Laurus Labs’ proposed generic version of a drug for the treatment of a lung disease called idiopathic pulmonary fibrosis would infringe 19 patents.
Roche is seeking a court order blocking copies until after the latest of the patents’ expirations, and to collect cash compensation if copies are made before then, according to complaint filed Jan. 14 in federal court in Wilmington, Del.
IPF results in scarring of the lungs, makes breathing difficult, and prevents vital organs from receiving enough oxygen to work properly. The median survival rate is 2-5 years after diagnosis. IPF is irreversible, with ...